
Commentary|Videos|May 28, 2025
CMSC Live: 2025 Annual Meeting Day 1
Host Jeffrey Wilken, PhD, chats with Marie Namey, APRN, MSCN, about the first day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Advertisement
Episodes in this series
Host
- Jeffrey Wilken, PhD
President-Elect,Consortium of Multiple Sclerosis Centers (CMSC); assistant professor of neurology, Georgetown University; director of Research, Neuropsychology Associates of Fairfax; executive director, Washington Neuropsychology Research Group
Guest
- Marie Namey, APRN, MSCN
Independent nurse consultant focusing on multiple sclerosis in University Heights, Ohio
Segment Breakdown
- 00:00 – Jeffrey Wilken, PhD, introduces the meeting and honors June Halper, emphasizing her foundational role and the meeting’s theme of comprehensive MS care as a tribute.
- 01:30 – Marie Namey, APRN, MSCN, expresses deep personal connection to June and shares the emotional process of preparing a lecture that honored her mentor and friend.
- 03:30 – Marie Namey, APRN, MSCN, recounts the origins of comprehensive MS care and highlights the importance of understanding this history, especially for new attendees.
- 05:30 – She emphasizes the legacy of CMSC’s founding figures and the need to pass that knowledge to the next generation of MS care providers.
- 07:00 – Marie Namey, APRN, MSCN, identifies interdisciplinary teamwork as a major challenge for new providers, especially in the wake of more siloed practices post COVID.
- 08:15 – Discussion shifts to the financial barriers patients face and the expanding roles of team members like pharmacists and social workers in comprehensive care.
- 9:25 – Marie Namey, APRN, MSCN, shares that networking and long-standing relationships are her favorite part of CMSC, which fosters a community of shared values in MS care.
- 10:00 - Jeffrey Wilken, PhD, closes by thanking Marie for her heartfelt lecture and looks forward to continuing the conference on the following day.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
2
POLARIS-AD Phase 3 Trial of PDE5 Inhibitor AR1001 Completes Treatment Phase With Favorable Safety Profile
3
AD109 Accepted NDA, AXS-12 FDA Submission, Phase 2 CELIA Study Results
4
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
5



















